- Little Green Pharma (LGP) has received a $2.5 million purchase order from DEMECAN for 21,300 units of its medicinal cannabis flower medicine
- This is the fourth order DEMECAN has placed, following 500, 9000 and 17,000 units for delivery in CYQ1, CYQ2 and CYQ3, respectively
- This new order brings DEMECAN’s total orders to 47,800 units for a total cost of $5.7 million in CY21 alone
- To capitalise on the growing demand, Little Green Pharma has brought its existing cultivation facilities to full capacity
- Shares in Little Green Pharma are up 9.02 per cent and are trading at 66.5 cents
Little Green Pharma (LGP) has received a $2.5 million purchase order from DEMECAN for 21,300 units of its medicinal cannabis flower medicine.
Based in Germany, DEMECAN is a pharmaceutical wholesaler that covers all the manufacturing steps from cultivation, processing, storage and delivery.
This is the fourth order DEMECAN has placed, following 500, 9000 and 17,000 units for delivery in CYQ1, CYQ2 and CYQ3, respectively.
This new order brings DEMECAN’s total orders to 47,800 units for a total cost of $5.7 million in CY21 alone.
To capitalise on the growing demand, Little Green Pharma has brought its existing cultivation facilities to full capacity.
Managing Director Fleta Solomon commented: “This order means a lot more than just the value of the sales it represents, it’s tangible evidence of the success of our strategy.”
“We are currently in a position where all flower product we produce is sold into Australia and overseas markets and we have customers looking for more.
“It heightens the urgency for us to focus on increasing our production capacity to capitalise on the brand equity we have built in the market.”
Shares in Little Green Pharma are up 9.02 per cent and are trading at 66.5 cents at 2:10 pm AEST.